Redeye comments on GiG’s Q2-results which were in line with expectations and the preliminary outcome...
Nanexa presented strong validation of its PharmaShell technology during the first half of 2025, with...
Redeye provides an in-depth review of AcouSort’s Q2 report and activities during and after the quart...
Redeye is impressed by the strong delivery from GomSpace during the last two quarters, posting stell...
Redeye initiates coverage of BICO, a leading player in the bioconvergence space.
Redeye makes a correction to our estimates, slightly impacting our fair value range.
* Enedo drove the 6% Q2 adj. EBITA miss while Inission beat by 4% * 1.
* Europe and other markets continue to perform, North America less so * We reset our expectations-po...
Q2-rapporten överraskade positivt med stark orderingång och förbättrad lönsamhet, även om nettoomsät...
Atria plans EUR 16m investment in its Kauhajoki plant to modernise production and reorganise beef pr...
Redeye comments on the Q2 report. Top-line figures came in broadly in line with our expectations.
Nettoomsättningen för det andra kvartalet 2025 uppgick till 142,1 MSEK (114,2), motsvarande en organ...
New Wave Groups Q2-rapport var svagare än väntat med lägre omsättning och resultat, främst tyngt av ...
Oncopeptides (ONCO) is a Swedish biotech that aims to develop and commercialise therapies for diffic...
Redeye is positive to GomSpace’s Q2 report published this morning, where the company slightly exceed...
* Pome project schedule delayed * Lower-than-expected project margins in Pome and Pienava * We cut '...
Redeye notes that Smart Eye’s Q2 reflected underlying solid performance, with Smart Eye reaching a k...
Redeye updates its view on Xbrane following its Q2 report.
Redeye updates on Gentoo Media after weaker-than-expected Q2 results and lowered full-year 2025 guid...
Redeye provides an update following Corline’s Q2 2025 report.
